HCA executives have enlisted the Nashville office of Gresham Smith & Partners to design the North Gulch buildings that will house the hospital operator's Sarah Cannon Research Institute and Parallon Business Solutions divisions, according to multiple sources who asked to go unnamed. The Gresham website has no image of the buildings and no renderings have been released. HCA has yet to disclose the number of office towers it will construct at the 10.8-acre site on Charlotte Avenue. Read more about the project here.
Nashville-based developer Alex S. Palmer & Co. has landed an equity partner to help jumpstart its long-stalled West End Summit project in Midtown, according to The Tennessean.
Palmer will team with Atlanta-based TPA Group to help finance construction of the three-building development, the morning daily reports.
HCA, whose Parallon Business Solutions and Sarah Cannon Research Institute subsidiaries are to anchor two of the three towers, has said it is considering other sites given the uncertainty of West End Summit. In addition, InterContinental Hotels & Resorts is to have a hotel presence in the middle tower. However, the company has since removed the WES site from its website.
Sarah Cannon Research Institute executives are teaming up with global pharmaceutical giant AstraZeneca to discover and refine the development of cancer treatments. Sarah Cannon will help AstraZeneca find patients for clinical trials, building on the relationship the two entities have had since 2010.
Specifically, the parties will work together on molecular profiling to classify tissue based upon genetic profiles for the purpose of treating cancers and predicting response to therapy.
“Through our research, we know how vital and impactful individualized treatment options are for patients battling this complex disease,” said Dee Anna Smith, chief executive officer of SCRI. “By partnering with AstraZeneca, we are expanding opportunities to accelerate drug development and deliver more targeted therapies to patients who urgently need them.”
Sarah Cannon Research Institute, the Nashville-based cancer arm of HCA International, and UCL-Advanced Diagnostic (part of the UCL Cancer Institute), will team to develop a genetic profiling laboratory in London.
The London-based laboratory introduces new techniques that allow doctors to discover the gene alterations which drive cancer and to deliver these as diagnostic tests. This will allow doctors to better decide what treatment is most appropriate. This approach, called ‘precision or personalised medicine’, is of particular interest in difficult cases where standard therapies are not working or not defined.
The laboratory introduces a new method, developed by UCL scientists, for the detection of mutations in a large number of genes in a single test. The test also uses the same samples as existing pathology tests rather than requiring fresh tissue. These innovations combine to make genetic profiling considerably cheaper and more practical to carry out by health services than other techniques developed to date.